Zobraziť v EDS

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

Uložené v:
Podrobná bibliografia
Názov: Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer
Autori: John Bridgewater, Morten Mau-Sørensen, Juan W. Valle, Magnus Lydolph, Jennifer J. Knox, Mairéad G McNamara, Ulrik Lassen, Mark Jitlal, Harpreet Wasan, Lars Henrik Jensen, Ib Jarle Christensen, Mie Grunnet
Zdroj: Grunnet, M, Christensen, I J, Lassen, U, Jensen, L H, Lydolph, M, Knox, J J, McNamara, M G, Jitlal, M, Wasan, H, Bridgewater, J, Valle, J W & Mau-Sorensen, M 2015, ' Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer ', European Journal of Cancer, vol. 51, no. 11, pp. 1381-1388 . https://doi.org/10.1016/j.ejca.2015.04.011
Grunnet, M, Christensen, I J, Lassen, U, Jensen, L H, Lydolph, M, Knox, J J, McNamara, M G, Jitel, M, Wasan, H, Bridgewater, J, Valle, J W & Mau-Sorensen, M 2015, 'Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer', Eur J Cancer, vol. 51, no. 11, pp. 1381-8. https://doi.org/10.1016/j.ejca.2015.04.011
Informácie o vydavateľovi: Elsevier BV, 2015.
Rok vydania: 2015
Predmety: Adult, Male, 0301 basic medicine, CA-19-9 Antigen, Phase I as Topic, survival, Cohort Studies, 03 medical and health sciences, Clinical Trials, Phase II as Topic, 0302 clinical medicine, 80 and over, Humans, Clinical Trials, Prospective Studies, Aged, Randomized Controlled Trials as Topic, Retrospective Studies, Aged, 80 and over, Bile duct cancer, CA 19-9, survival, Clinical Trials, Phase I as Topic, Phase II as Topic, Bile duct cancer, Middle Aged, CA19-9, Prognosis, Bile duct cancer Biomarkers CA19-9 Response to therapy ADVANCED PANCREATIC-CANCER BILIARY-TRACT CANCER CA-19-9 LEVELS GEMCITABINE ANTIGEN ADENOCARCINOMA CISPLATIN, Survival Analysis, 3. Good health, CA-19-9 Antigen/blood, Bile Duct Neoplasms, CA 19-9, Female, Bile Duct Neoplasms/blood, Response to therapy, Biomarkers
Popis: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer.Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.Patients meeting the criteria to be included were 54 in the investigational cohort and 34, 68 and 148 in the three validation sets, respectively. Multivariate analysis included radiological response, performance status, bilirubin, gender, site of cancer, extend of disease, CA19-9 at baseline and age. A hazard ratio (HR) of 0.60 (95%CI: 0.44-0.80, p = 0.0005) for death in CA19-9 responders was reached in the investigational cohort. The predictive value of CA 19-9 response was confirmed in all three validation cohorts.CA19-9 response is a robust predictor of survival in patients with inoperable bile duct cancer in four independent data sets.
Druh dokumentu: Article
Jazyk: English
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2015.04.011
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/25971532
https://christie.openrepository.com/handle/10541/558728
https://www.research.manchester.ac.uk/portal/en/publications/decline-in-ca199-during-chemotherapy-predicts-survival-in-four-independent-cohorts-of-patients-with-inoperable-bile-duct-cancer(882613eb-e6a6-4cbd-a26d-494c7cf15788).html
http://europepmc.org/abstract/MED/25971532
https://www.ncbi.nlm.nih.gov/pubmed/25971532?format=text
http://www.sciencedirect.com/science/article/pii/S0959804915003470
https://www.sciencedirect.com/science/article/pii/S0959804915003470#!
https://portal.findresearcher.sdu.dk/da/publications/fccfc7d5-a74d-4be7-8d21-0f788d91bc58
Rights: Elsevier TDM
Prístupové číslo: edsair.doi.dedup.....6cabd3ab4df4d6abc6ac75e9d4745e9d
Databáza: OpenAIRE
Popis
Abstrakt:Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer.Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.Patients meeting the criteria to be included were 54 in the investigational cohort and 34, 68 and 148 in the three validation sets, respectively. Multivariate analysis included radiological response, performance status, bilirubin, gender, site of cancer, extend of disease, CA19-9 at baseline and age. A hazard ratio (HR) of 0.60 (95%CI: 0.44-0.80, p = 0.0005) for death in CA19-9 responders was reached in the investigational cohort. The predictive value of CA 19-9 response was confirmed in all three validation cohorts.CA19-9 response is a robust predictor of survival in patients with inoperable bile duct cancer in four independent data sets.
ISSN:09598049
DOI:10.1016/j.ejca.2015.04.011